Clarity is a clinical stage radiopharmaceutical company developing next-generation products to address the growing need for the use of radiopharmaceuticals in oncology. Clarity is a global leader in Targeted Copper Theranostics (TCT), developed with its proprietary SAR Technology platform. TCT are the next-generation disruptive platform in radiopharmaceuticals that employ the "perfect pairing" of copper-64 and copper-67 for diagnosis and therapy. TCT deliver a compelling combination of high accuracy and high precision in the treatment of a range of cancers, as well as providing supply and logistical advantages over current theranostics. TCT provide a highly efficacious, scalable, and cost-effective way to expand radiopharmaceuticals into the global oncology market. Clarity has a diverse range of products in clinical trials which address both large indications (prostate cancer and breast cancer) as well as small and orphan indications (neuroendocrine tumours (NETs) and neuroblastoma) of cancer. Our ultimate goal is to improve treatment outcomes for children and adults with cancer.
该公司进入各个市场的顺序 — 从最早到最新
注册以查看完整信号动态
Clarity Pharmaceuticals 的国际扩张与竞争对手的对比情况
Clarity Pharmaceuticals你条形图显示所对比公司之间的相对规模。
列5| 公司 | 市场 | 新市场 | 势头 | 活动 | 扩张评分 |
|---|---|---|---|---|---|
 Clarity Pharmaceuticals你 | 0 | 0 | 0% | 0 | 32 |
Head of Clinical Development
查看职位Sydney, New South Wales, Australia · 3周前
Senior Manager, People & Culture
查看职位United States · 4个月前
Clinical Data Analyst and Statistical Programmer
查看职位Sydney, New South Wales, Australia · 4个月前
没有进行中的营销活动
注册以跟踪该公司，并在发生变化时第一时间获得提醒。
Clarity Pharmaceuticals的67Cu-SAR-bisPSMA前列腺癌SECuRE试验完成剂量递增，显示有希望的疗效和安全性，并进入二期扩展。
Clarity Pharmaceuticals 开始 SECuRE 试验的队列扩展阶段，首次使用 67Cu-SAR-bisPSMA 治疗转移性去势抵抗性前列腺癌患者。
Clarity制药公司开始64Cu-SAR-bisPSMA的第三期试验，用于检测前列腺癌复发，旨在获得FDA批准作为诊断剂。
解锁已验证邮箱与直拨电话
免费 · 无需信用卡
关于 Clarity Pharmaceuticals 的业务、市场和增长信号的快速解答。
